Project Grant K08HL171896
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$166K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded this $145,642 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Leland Stanford Junior University. The funding supports a 2-year research project to investigate the molecular mechanisms that regulate mitochondrial calcium uptake, a key process influencing cellular energetics and heart disease pathogenesis. The research training plan involves using a multidisciplinary approach including...
The National Heart, Lung, and Blood Institute (NHLBI) awarded The Leland Stanford Junior University a $433,824 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research aimed at understanding the metabolic mechanisms underlying diabetic cardiomyopathy. The project will leverage induced pluripotent stem cell (iPSC) technology to generate cardiovascular cell models of type 2 diabetes and assess the impact of SGLT2 inhibition on cellular and metabolic...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $717,246 to The Leland Stanford Junior University to conduct research focused on understanding the molecular mechanisms underlying cardiovascular toxicity caused by proteasome inhibitor cancer drugs, particularly carfilzomib. The key objectives are to leverage mouse models, human induced pluripotent stem cells, gene editing...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $259,464 to The Leland Stanford Junior University to study the combined effects of mitochondria-based therapies and guideline-directed medical therapy (GDMT) for treating heart failure.
The key objectives are to: 1) Determine the protective mechanisms of mitochondria-rich extracellular vesicles (M-EVs) in combination with GDMT using an...
This $167,864 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a study to investigate risk stratification and outcomes across the spectrum of immune checkpoint inhibitor (ICI) cardiotoxicity. The key objectives are to:
Retrospectively examine cardiac and oncologic outcomes associated with ICI cardiotoxicity, stratified by patient symptoms and troponin-I measurements.
Retrospectively...
The National Heart, Lung, and Blood Institute (NHLBI) awarded The Leland Stanford Junior University (Stanford University) a $1,204,160 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to evaluate the potential of activating the AMPK-BACH1-NRF2 signaling pathway as a therapeutic target for treating inherited forms of dilated cardiomyopathy (DCM). The research aims to determine the selectivity of this pathway for restoring contractile function in different genetic...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will fund research to investigate the role of macrophages and CXCR3+ T-cells in the development of immune checkpoint inhibitor (ICI)-induced myocarditis. The $117,804 grant awarded to The Leland Stanford Junior University will be used to: 1) study the effects of CXCR3 blockade in a mouse model of ICI myocarditis, and 2) examine the mechanistic...
The federal Project Grant award F30HL174099 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The $125,568.00 award supports research conducted by The Leland Stanford Junior University to investigate the molecular mechanisms governing the transport and regulation of nicotinamide adenine dinucleotide (NAD+) within the mitochondrial matrix. This research aims to elucidate how mitochondria maintain adequate...
The federal Project Grant award F32HL167558, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will support research to investigate the role of the unfolded protein response (UPR) in genetic dilated cardiomyopathy (DCM). The $159,512 award to The Leland Stanford Junior University will be used to study how impaired proteostasis and ER stress contribute to cardiac dysfunction in DCM, with a focus on the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,543,676 to The Leland Stanford Junior University to develop a multi-physics cardiac simulator to support surgical planning for patients with complex congenital heart disease (CHD). The key products to be delivered include:
Rapid patient-specific 3D modeling techniques using machine learning to construct anatomic models of unique CHD...